FlandersBio on Twitter

Follow us on Twitter

Archive for April 2016 - News

Archive for April 2016 - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

World’s first population-level microbiome study reveals links between lifestyle and gut flora


The Flemish Gut Flora Project, one of the largest population-wide studies on gut flora variation among healthy volunteers, has presented its first major results. Through the analysis of more than 1,000 human stool samples, a team of researchers led by professor Jeroen Raes (VIB/VUB/KU Leuven) has identified 69 factors that are linked to gut flora composition. These results provide important information for future disease research and clinical studies. The project’s fundamental insights will be published in the upcoming issue of the leading academic journal Science. read more

Galapagos and AbbVie expand their cystic fibrosis collaboration


Galapagos NV (Euronext & NASDAQ: GLPG) and AbbVie (NYSE: ABBV) announce that the companies have expanded their agreement in cystic fibrosis (CF) to reflect the successful expansion of their CF portfolio. Companies have agreed to increase the potential milestones to Galapagos for Phase 1 and 2 achievements, bringing the remaining total milestones in the CF alliance up to approximately $600 million, from $350 million. Other key collaboration terms remain in place: tiered royalty payments on net sales, ranging from mid-teens to twenty percent. Galapagos retains commercial rights to China and South Korea, and has an option to co-promote in Belgium, Netherlands, and Luxembourg. read more

ESPERITE (ESP) financial results for 2015 published


ESPERITE N.V. has published today its Annual Report for the year ended 31st December 2015. The 2015 Annual Report is now available on the Company's website www.esperite.com read more



Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that it has received an undisclosed milestone payment from its collaboration with Novartis. The payment was triggered by the clearance of the Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for the Novartis Phase I study with a Nanobody that binds with an undisclosed GPCR target in inflammation[1]. The Phase I study is expected to start in Q2 2016. read more

Galapagos kick-starts 2016 with Q1 cash position of €988 M


Galapagos NV (Euronext & NASDAQ: GLPG) announces its unaudited first quarter results, which are further detailed in an online Q1 2016 report published on the Galapagos website, www.glpg.com. read more

ThromboGenics NV : New Ocriplasmin Research Findings Presented at Upcoming ARVO 2016 Annual Meeting in Seattle


ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company, focused on developing innovative treatments for back of the eye diseases, announces that the Company will be presenting a number of scientific posters and presentations at the upcoming Association for Research in Vision and Ophthalmology (ARVO) 2016 Annual Meeting. The Meeting is being held from May 1st - 5th, 2016 in Seattle, US. read more

Genohm releases the new 5.1 version of SLims


the new SLims version 5.1 has been released. read more

Biocartis strengthens biomarker portfolio for colorectal cancer


Biocartis (Euronext Brussels: BCART), an innovative molecular diagnostics company, today announces the exclusive licensing of a recently detected set of mutations in the Epidermal Growth Factor Receptor (EGFR)[1] that give resistance to anti-EGFR therapies in colorectal cancer. The aim is to integrate these biomarkers into molecular diagnostic tests for the Idylla(TM) platform, to enhance their ability to monitor therapy resistance in patients and thereby allowing physicians to optimise treatment selection. read more

Celyad receives certification for C-Cure® non-clinical data from the European Medicines Agency (EMA)


Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in the discovery and development of engineered cell therapies, with clinical programs in cardiovascular disease and immuno-oncology, today announced that the EMA has issued a certification for C-Cure® non-clinical data. read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top